Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

@article{Shimamura2007Interleukin4CT,
  title={Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.},
  author={Takeshi Shimamura and Richard E. Royal and Mitomu Kioi and Atsushi Nakajima and Syed Rafat Husain and Raj K. Puri},
  journal={Cancer research},
  year={2007},
  volume={67 20},
  pages={9903-12}
}
Targeting cell surface receptors with cytotoxins or immunotoxins provides a unique opportunity for tumor therapy. Here, we show the efficacy of the combination therapy of gemcitabine with an interleukin-4 (IL-4) cytotoxin composed of IL-4 and truncated Pseudomonas exotoxin in animal models of pancreatic ductal adenocarcinoma (PDA). We have observed that 42 of 70 (60%) tumor samples from patients with PDA express moderate- to high-density surface IL-4 receptor (IL-4R), whereas normal pancreatic… CONTINUE READING